Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTXNASDAQ:IDRANASDAQ:INMBNASDAQ:MBOTNASDAQ:ONVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.95+2.1%$2.04$1.41▼$2.79$86.81M1.4667,467 shs18,161 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsINMBINmune Bio$2.61+10.4%$6.98$1.89▼$11.64$55.66M1.34778,332 shs4.70 million shsMBOTMicrobot Medical$2.60+4.0%$2.55$0.82▼$3.38$90.94M1.131.77 million shs2.06 million shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+2.09%-2.26%-6.02%+21.88%+18.90%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INMBINmune Bio+10.38%-58.52%-64.17%-64.17%-67.40%MBOTMicrobot Medical+4.00%+4.42%-4.76%+74.50%+147.62%ONVOOrganovo0.00%0.00%0.00%-3.77%-77.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio2.653 of 5 stars3.55.00.00.00.00.80.0IDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINMBINmune Bio1.6236 of 5 stars3.30.00.00.02.11.70.6MBOTMicrobot Medical2.0101 of 5 stars3.52.00.00.02.40.00.6ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 3.00Buy$10.00412.82% UpsideIDRAIdera Pharmaceuticals 0.00N/AN/AN/AINMBINmune Bio 2.57Moderate Buy$18.40606.33% UpsideMBOTMicrobot Medical 3.00Buy$9.00246.15% UpsideONVOOrganovo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MBOT, INMB, ONVO, IDRA, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold4/10/2025MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$180K492.38N/AN/A$0.23 per share8.48IDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AINMBINmune Bio$10K6,142.59N/AN/A$1.45 per share1.80MBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/AONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AINMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)MBOTMicrobot Medical-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)ONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/ALatest MBOT, INMB, ONVO, IDRA, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MBOTMicrobot Medical-$0.15-$0.08+$0.07-$0.08N/AN/A5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 million5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A13.0713.07IDRAIdera PharmaceuticalsN/A1.561.56INMBINmune BioN/A2.642.64MBOTMicrobot MedicalN/A16.1916.19ONVOOrganovoN/A0.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%IDRAIdera Pharmaceuticals12.18%INMBINmune Bio12.72%MBOTMicrobot Medical16.30%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.38%IDRAIdera Pharmaceuticals5.05%INMBINmune Bio35.70%MBOTMicrobot Medical4.74%ONVOOrganovo3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2045.45 million40.73 millionOptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableINMBINmune Bio1023.58 million15.17 millionOptionableMBOTMicrobot Medical2036.38 million34.65 millionOptionableONVOOrganovo201.70 million14.79 millionOptionableMBOT, INMB, ONVO, IDRA, and ENTX HeadlinesRecent News About These CompaniesDriven! The Onvo L60 Is China’s Best Tesla Model Y Killer to DateMay 18, 2025 | msn.comTwo new option listings and one option delisting on April 24thApril 25, 2025 | markets.businessinsider.comVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ MarketApril 24, 2025 | globenewswire.comOrganovo announces VivoSim to carry forward 3D bioprinting, legacy techApril 23, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol "VIVS"April 23, 2025 | quiverquant.comQVivoSim to Carry Forward Organovo 3D BioprintingApril 23, 2025 | globenewswire.comOrganovo expects to meet requirements for continued listing on NasdaqApril 2, 2025 | markets.businessinsider.comOrganovo Holdings Expects to Meet Nasdaq Listing RequirementsApril 2, 2025 | tipranks.comOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | financialpost.comFOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | globenewswire.comOrganovo sees cash runway through the end of FY26March 28, 2025 | markets.businessinsider.comOrganovo, Inc.: Organovo Provides Business UpdateMarch 27, 2025 | finanznachrichten.deOrganovo Provides Business UpdateMarch 27, 2025 | financialpost.comFOrganovo Provides Business UpdateMarch 27, 2025 | globenewswire.comOrganovo, Inc.: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 26, 2025 | finanznachrichten.deOrganovo closes sale of FXR program to Eli LillyMarch 25, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Completes Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | quiverquant.comQOrganovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | globenewswire.comOrganovo Announces 1-for-12 Reverse Stock Split To Maintain Nasdaq ComplianceMarch 21, 2025 | nasdaq.comOrganovo trading halted, news pendingMarch 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBOT, INMB, ONVO, IDRA, and ENTX Company DescriptionsEntera Bio NASDAQ:ENTX$1.95 +0.04 (+2.09%) As of 07/3/2025 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Idera Pharmaceuticals NASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.INmune Bio NASDAQ:INMB$2.60 +0.25 (+10.38%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$2.55 -0.06 (-2.11%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Microbot Medical NASDAQ:MBOT$2.60 +0.10 (+4.00%) Closing price 07/3/2025 03:49 PM EasternExtended Trading$2.62 +0.02 (+0.62%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
